ÎÚÑ»´«Ã½

Jump to Main Content

Newsroom

ASH, the world's largest professional society concerned with the causes and treatments of blood disorders, regularly issues press releases highlighting clinical and research advances announced at the ASH annual meeting and published in Blood, as well as releases and statements on breaking policy news affecting the field of hematology.

News and Press Releases

Heightened Risk of Hospitalization for Blood Clots Seen in People with Long-Term Exposure to Air Pollution
Dec. 17, 2024

Stem Cell Transplant Offers No Additional Benefit for Patients with Mantle Cell Lymphoma in Deep Remission
Dec. 10, 2024

Undergoing Stem Cell Transplant for Sickle Cell Disease in Childhood Improves Quality of Life a Decade Later
Dec. 10, 2024

Genetic Profile Correlates with Better Response to Treatment for Myeloproliferative Neoplasms
Dec. 10, 2024

Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma
Dec. 10, 2024

ASH Identifies Strategies and Barriers for Implementing DEI in Clinical Trials
Dec. 9, 2024

ASH Newborn SCD Screening Program in Sub-Saharan Africa Found Feasible
Dec. 8, 2024

Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
Dec. 8, 2024

Universal Duffy Testing is Likely Cost Effective for U.S. Population
Dec. 7, 2024

Disease-Modifying Therapies Remain Underused in SCD Despite Safety and Efficacy
Dec. 7, 2024

Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood Disorders
Dec. 7, 2024

Studies Highlight Interactions Among Lifestyle Factors, Disease Development, and Response to Treatment
Dec. 7, 2024

Putting Women and Children First to Optimize Their Hematology Health
Dec. 7, 2024

ASH Inclusion Program Retained and Engaged Hematologists Underrepresented in Field, 20-Year Analysis Shows
Nov. 21, 2024

ASH Announces Recipients of 2024 ASH Advocacy Awards
Nov. 18, 2024

Medicaid Enrollment Continuity Tied to Lymphoma Stage at Diagnosis
Nov. 12, 2024

ASH Honors Dr. Judith Kleinerman with the 2024 Exemplary Service Award
Nov. 8, 2024

ASH Names New Blood Editor-in-Chief
Oct. 31, 2024

New Leadership Elected to the ÎÚÑ»´«Ã½
Oct. 28, 2024

ASH Announces Editors-in-Chief of Two New Blood Journals
Oct. 9, 2024

Food Deserts, Limited Access to Transportation Linked to More Complications Among Preschool Children with SCD
Oct. 7, 2024

Cilta-cel Found Highly Effective in First Real-World Study
Oct. 4, 2024

CAR-T Safe and Effective on an Outpatient Basis in Community Hospitals
Sep. 30, 2024

ASH Announces Sickle Cell Disease Research Priorities to Accelerate Treatments and Comprehensive Care
Sep. 25, 2024

Stroke Rates Increasing in Individuals Living with SCD Despite Treatment Guidelines
Sep. 20, 2024

Study Finds Unique Pattern of Blood Clots in Sickle Cell Trait, but Low Overall Clot Risk
Sep. 12, 2024

ASH Recognizes 2024 Quality Improvement Champions
Aug. 27, 2024

ASH Announces New ASH-Harold Amos Medical Faculty Development Program Hematology Scholar
Aug. 20, 2024

Over Half of Iron Deficiency Cases in Large Health System Still Unresolved at Three Years
Aug. 15, 2024

External Mentorship Key in Encouraging Trainees to Pursue Classical Hematology
Aug. 01, 2024

FDA-Mandated CAR-T Monitoring Period Could be Halved
Jul. 24, 2024

Hydroxyurea Does Not Reduce Ovarian Reserve in Female Patients With Sickle Cell Disease
Jul. 18, 2024

Safe, Successful Pregnancies Possible After AlloHCT
Jul. 15, 2024

Reduced Infections Seen in CLL and NHL Patients Undergoing Immunoglobin Testing and Replacement Therapy
Jun. 21, 2024

ASH Announces 2024 Honorific Award Recipients
Jun. 18, 2024

Afib Patients on Low Doses of Blood Thinners Have More Bleeding Episodes Than Those on Standard Doses
Jun. 06, 2024

Gaps in Transition From Pediatric to Adult Care for Individuals Living with Sickle Cell Disease Associated with More Hospital Visits
May. 29, 2024

Anti-Diabetic Treatment Associated with Reduced Risk of Developing Blood Cancer
May. 17, 2024

ASH Announces 24 Institutions Selected for Duffy Status Health Equity Project
May. 15, 2024

Older Adults with Aggressive Blood Cancer are Responsive to Treatment and Show Prolonged Survival
May. 09, 2024

Stem Cell Transplants and Survival Rates on the Rise Across All Racial and Ethnic Groups
Apr. 25, 2024

ASH Research Collaborative and Reagan-Udall Foundation for the FDA Launch Sickle Cell Disease Real-World Data Project
Apr. 17, 2024

ASH Names Editor-in-Chief of New Journal Blood Global Hematology
Apr. 16, 2024

Study Shows Feasibility of Ending Specialist Follow-Up in Patients with Low-Risk CLL
Apr. 04, 2024

MRI and Lumbar Puncture Not Necessarily Required to Manage CAR T-Cell Therapy Complications
Mar. 19, 2024

T-cell Malignancies Represent Small Fraction of the Reported Secondary Cancers following CAR-T in the FDA’s Adverse Event Reporting System
Mar. 14, 2024

ASH Statement on Introduction of Health Home Legislation for People Living with Sickle Cell Disease
Feb. 29, 2024

Combination Therapy Lowers Blood Pressure in Patients Receiving Ibrutinib
Feb. 5, 2024

ÎÚÑ»´«Ã½ Announces 2024 Scholar Award Recipients
Feb. 1, 2024

ASH Supports CMMI’s Cell & Gene Therapy Access Model for Sickle Cell Disease
Jan. 31, 2024

Obesity Linked to Detection of Blood Cancer Precursor
Jan. 12, 2024

Mohandas Narla, DSc, Begins Term as 2024 ASH President
Jan. 09, 2024

Liso-cel is a Cost Effective Second-line Treatment for Common Form of Lymphoma
Dec. 28, 2023

Study Finds That Severe Long-Term Complications of Pulmonary Embolism in Children Are Rare
Dec. 26, 2023

Study Suggests COVID-19 Vaccine Safe and Effective for Individuals with Sickle Cell Disease
Dec. 18, 2023

Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia
Dec. 12, 2023

Modified Stem Cell Transplant Procedure Shows Favorable Results in Adults Living with Severe Sickle Cell Disease
Dec. 12, 2023

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma
Dec. 12, 2023

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Outperforms VRd Alone for Multiple Myeloma
Dec. 12, 2023

ASH Recognizes Senator Chris Van Hollen with 2023 Public Service Award
Dec. 11, 2023

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches
Dec. 10, 2023

Research Reveals Opportunities to Better Address Blood Disorders Early in Life
Dec. 09, 2023

Studies Highlight Impacts of Applying New Technologies in Everyday Care
Dec. 09, 2023

Studies Uncover Drivers of Health Disparities and Opportunities to Enhance Equity
Dec. 09, 2023

ASH Statement on FDA’s Approval of New Sickle Cell Disease Gene Therapy
Dec. 08, 2023

ASH to Recognize Guideline Implementation Champions at 65th Annual Meeting
Dec. 07, 2023

The ÎÚÑ»´«Ã½ Honors Dr. Elaine Muchmore with the 2023 Exemplary Service Award
Dec. 06, 2023

Blood Clotting Risk Quickly Drops After Stopping Hormonal Contraceptives
Nov. 08, 2023

Individuals with Severe Sickle Cell Disease Express High Risk Tolerance for Gene Therapies
Oct. 31, 2023

New Leadership Elected to the ÎÚÑ»´«Ã½
Oct. 26, 2023

CAR T Cell Therapy Effective in Patients with Blood Cancer Regardless of Race
Oct. 19, 2023

ASH Recognizes 2023 Choosing Wisely Champions
Oct. 2, 2023

Pneumococcal Vaccines Linked with Fewer Severe Infections Among Children with Sickle Cell Disease
Sep. 12, 2023

ASH Names Editors-in-Chief of New Blood Journals
Sep. 8, 2023

Patients with AML Who Received Vitamin C/D Supplements Had Fewer Complications, But No Overall Survival Benefit Seen
Sep. 6, 2023

ASH Announces New ASH-AMFDP Hematology Scholars
Aug. 23, 2023

First-of-its-Kind Study Reveals Predictive Factors for Outcomes of AdvancedStage AL Amyloidosis
Aug. 15, 2023

Obesity and High Weight Linked to Adverse Outcomes in Leukemia Treatment
Jul. 11, 2023

ASH Advocates for Diversity in Medicine
Jun. 30, 2023

ASH Announces the 2023 Honorific Award Recipients
Jun. 28, 2023

Study Uncovers Direct Link Between Blood Group A and a Higher Risk for COVID-19 Infection
Jun. 27, 2023

New Data Informs Treatment of Blood Cancer During Pregnancy
Jun. 1, 2023

Statement on New ASH Clinical Practice Guidelines on Thrombophilia
May 17, 2023

Criteria for Selecting Who Can Enroll in Multiple Myeloma Clinical Trials May Exclude Patients from Racial and Ethnic Minorities
May 4, 2023

Extreme Poverty a Key Driver for Relapse in Kids With ALL
Apr. 18, 2023

A Promising Outlook: CAR T Cells Improve Patient Quality of Life
Mar. 30, 2023

ASH President Commends Reintroduction of Sickle Cell Disease Medicaid Demonstration Program
Mar. 22, 2023

Quantifying the Life Expectancy Gap for People Living with Sickle Cell Disease
Mar. 16, 2023

View All

Protect Medical Research

Urge your members of Congress to support continued medical research funding.

Take Action